Respecting Patient Curiosity in the Age of AI: How Oncology Teams Can Respond to Unproven Cancer Therapies

We are in an age in which patients have access to myriad resources, including artificial intelligence (AI) and media saturated with conflicting opinions. These channels have become primary sources as patients form their own conclusions about managing cancer treatment. This environment has made discussions about treatment options increasingly complex, challenging both providers and patients to discern what is and is not beneficial. Yet this is also a pivotal moment: If we choose to engage rather than retreat, we can use these conversations to build trust and protect patients from harm.

In an era where patients arrive armed with AI-generated treatment ideas and social media anecdotes, outright dismissal of their questions jeopardizes trust and may drive them toward unsafe practices. Oncology teams must proactively integrate structured, empathetic conversations about non–evidence-based therapies into routine care rather than avoiding or minimizing these topics. The goal is not to endorse unproven interventions but to recognize that how we respond can either strengthen or fracture the therapeutic relationship.

Imagine the frustration Alexander Fleming or Albert Calmette may have felt when their groundbreaking ideas, such as using live bacteria and viruses to treat diseases, were dismissed and deemed too dangerous for human use. These innovations form the basis of therapies we rely on today. Patients today initiate discussions about therapies such as ivermectin and fenbendazole, both approved for other indications, and ask whether these drugs have a place in cancer treatment. When confronted with these suggestions, clinicians may feel their expertise and guideline-based approaches are being challenged by information from AI-generated sources and media outlets rather than by grounded, peer-reviewed evidence. This defensiveness can manifest in a dismissive response, such as, “I’m not treating a parasite, so let’s move on.” That moment is often the first instance of systematic disengagement from the patient.

The next patient may arrive after consulting a Chinese herbalist, seeking an Eastern medicine approach to cancer care. A reflexive dismissal, such as “There is no evidence,” risks leading the patient to perceive their oncologist or pharmacist as knowledgeable only in Western medicine. Such perceptions can snowball, leading patients to feel their provider is uncaring or, far worse, incompetent. They may then seek multiple second opinions or publicly critique the provider on internet platforms for “not being up to date” on their malignancy or proposed therapies. The original question about an unproven treatment has now become a broader crisis of trust.

How are we to practice today with both compassion and clarity while avoiding these discouraging outcomes? What strategies can prevent us from seeing patients only after they have exhausted unproven microdoses of antiparasitic agents or extreme starvation diets, returning with metastatic disease rather than potentially curable malignancies? We need to know the facts, understand the cultural and informational landscape in which our patients live, and adopt deliberate communication habits that keep them in our orbit.

Consider a patient with triple-negative breast cancer who asks about adding ivermectin to standard therapy. Rather than dismissing the idea, we can briefly acknowledge that only very early, small-scale clinical data exist, with limited and uncertain benefit. This underscores the investigational nature of this approach. We can explain that there is no regulatory approval for using fenbendazole or ivermectin in cancer treatment and that their potential toxicity—including bone marrow failure and severe cytopenias, even reported in approved veterinary settings—could permanently compromise their ability to receive effective, evidence-based therapy presently or in the future. Framing the discussion in terms of trade-offs (“This may add risk without clear benefit”) helps patients understand why we recommend against it without feeling belittled.

Dietary questions often present similar challenges. The Warburg effect and the phrase “sugar feeds cancer” are now part of lay vocabulary. Patients frequently arrive, even at chemotherapy education sessions, wanting to discuss what dietary modifications they can make to assist in their cancer journey. This is an excellent opportunity to invite conversation and, when appropriate, include or refer patients to dietitians for deeper counseling. We can acknowledge their desire to “do everything possible” while clarifying that cutting out all sugar is neither the most effective nor the safest strategy.

A brief, accessible explanation can go a long way. We can say that normal cells require glucose and that, even when dietary carbohydrates are restricted, the body will generate glucose to maintain adequate blood levels. Rather than debating metabolic pathways in detail, we can focus on risks patients understand: malnutrition, loss of lean muscle mass, increased fatigue, and potential treatment interruptions associated with extreme diets. We should also remain informed about emerging data, including paradoxical findings that some severe carbohydrate-restricted states may suppress primary tumor growth while promoting metastases in preclinical settings. The message is not that nutrition does not matter; it is that we do not yet have data supporting extreme, self-directed metabolic interventions as a safe substitute for evidence-based care.

Over time, I have found that a few simple communication habits can transform these high-risk conversations into opportunities for partnership. First, ask before you advise. Opening with, “What have you heard about this treatment, and what appeals to you about it?” surfaces the underlying fear or hope driving the request. Some patients and caregivers fear being “left behind” if they do not pursue or advocate for every option; others feel guilty if they are not “fighting hard enough.” Understanding the motivation allows us to address the real problem, such as fear of recurrence, desire for control, or concern about long-term adverse effects, rather than just the proposed therapy itself.

Second, validate and then reframe. Acknowledging the patient’s initiative by saying, “I’m glad you’re looking for every possible way to help your treatment work,” sets a collaborative tone. We can then outline what is known and unknown about the intervention’s efficacy and safety, as well as how it compares with standard options. This approach preserves the patient’s dignity while reinforcing our role as a trusted guide.

Third, offer a safe alternative next step. Instead of ending with “no,” offer a compromise. For example, “I don’t recommend ivermectin or fenbendazole because of the unknown risks and lack of benefit in your situation, but I would strongly recommend considering this clinical trial,” or “I do not support a strict ketogenic diet during chemotherapy, but let’s involve our dietitian to tailor a plan that supports your strength and treatment goals.” Providing a constructive option reassures the patient that we are not abandoning their desire to act, but that we have their best interest and safety in mind.

None of this work can rest solely on the oncologist. Addressing AI-driven misinformation and non–evidence-based therapies must be a multidisciplinary effort. Pharmacists can help contextualize off-label drug risks and drug-drug interactions. Dietitians can translate complex metabolic science into practical nutrition plans. Aligning messages across the team reinforces trust; conflicting responses from different clinicians quickly erode it.

Sustained, bidirectional education between patients and oncology teams must become routine, not an optional extra reserved for complex cases. By consistently inviting discussion of social media unsubstantiated claims, suggesting complementary therapies alongside input from various family and friends who have conducted their own online research, and responding in kind with empathy and evidence, we can protect patients from harm while preserving the trust that underpins effective cancer treatment. This is their journey, but it is our responsibility to guide them through it with respect, transparency, and scientific rigor.